Press Releases
  Date Title View
May 16, 2017
SAN DIEGO, May 16, 2017 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, announced today the completion of its previously announced underwritten public offering of 5,980,000 shares of its common s...
May 11, 2017
SAN DIEGO, May 11, 2017 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, announced today that it has priced an underwritten public offering of 5,200,000 shares of its common stock at a price to the p...
May 10, 2017
SAN DIEGO, May 10, 2017 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, announced today that it intends to offer and sell shares of its common stock in an underwritten public offering. Conatus also ...
May 4, 2017
SAN DIEGO, May 04, 2017 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced financial results for the first quarter ended March 31, 2017, and provided updates on its development programs. Conatus is developing emricasan, its first-in-class, orally active pan-caspase inhibitor, for the treatment of pati...
May 4, 2017
SAN DIEGO, May 04, 2017 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced that Novartis has exercised its option to an exclusive license for the global development and commercialization of emricasan, the company's first-in-class, orally-active pan-caspase inhibitor, under terms of the Option, Collabo...
Apr 27, 2017
SAN DIEGO, April 27, 2017 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced that it will report financial results for the first quarter ended March 31, 2017, after the market close on Thursday, May 4, 2017. Conatus will host a conference call and audio webcast at 4:30 p.m. Eastern Time on Thursday, M...
Apr 21, 2017
AMSTERDAM, the Netherlands, April 21, 2017 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) announced that two posters co-authored by Conatus employees are being presented today at The International Liver Congress™ 2017, the Annual Meeting of the European Association for the Study of the Liver (EASL) in Amsterd...
Mar 27, 2017
SAN DIEGO, March 27, 2017 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced the company's scheduled presentations at two upcoming investor conferences in New York: H.C. Wainwright NASH Investor Conference at 2:20 p.m. ET on Monday, April 3. 16...
Mar 15, 2017
SAN DIEGO, March 15, 2017 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced financial results for the fourth quarter and full year ended December 31, 2016, and provided updates on its clinical development programs. Conatus is developing emricasan, its first-in-class, orally active pan-caspase inhibit...
Mar 8, 2017
SAN DIEGO, March 08, 2017 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced that it will report financial results for the fourth quarter and full year ended December 31, 2016, after the market close on Wednesday, March 15, 2017. Conatus will host a conference call and audio webcast at 4:30 p.m. Eas...
1
...
NextLast
= add release to Briefcase